Riding the Wave: Medical Venture Capital Enters a Golden Era | Live Stream Preview

As a pillar of the national economy and an emerging industry closely tied to public welfare, the healthcare sector has garnered significant attention and experienced rapid development in recent years. From a global market perspective, driven by both technological advancements and growing demand, the healthcare industry has entered a golden age of rapid growth and is poised to become one of the leading sectors in the future global economy.

The COVID-19 pandemic, which erupted globally at the beginning of the year, has posed enormous challenges across various industries. However, the healthcare sector has stood out, particularly in areas closely linked to the epidemic. This has provided more sustainable stimulus and new windows of opportunity for the development of sub-sectors such as the vaccine industry, in vitro diagnostics (IVD), telemedicine, and health management consulting. Meanwhile, manufacturers of low-value medical consumables—such as gloves, protective suits, and face masks—which were previously overlooked, have also experienced rapid growth during this outbreak.

Meanwhile, in 2020, the healthcare sector saw a continuous rollout of policies. Initiatives such as “Internet + Medical Insurance,” adjustments to the National Reimbursement Drug List, the registration system for pharmaceutical sales representatives, the advancement of Diagnosis-Related Group (DRG) payment reforms, and the intensification of volume-based procurement have all exerted a profound impact on the industry.

The healthcare sector also delivered standout performance in the capital markets. In the first half of 2020 alone, China’s healthcare industry recorded 215 financing deals, an 18% year-on-year increase, with total funding reaching RMB 44.1 billion, up 46% year on year. Financing volume in the third quarter also hit a record high. Biopharmaceuticals remained the hottest sector attracting investment both domestically and internationally.

The U.S. market is the largest in the global healthcare industry and serves as a central hub for research, development, and innovation in biopharmaceuticals and medical devices. Meanwhile, China’s healthcare industry is undergoing a historic transition from a sales-driven large-scale market to an innovation-led powerhouse.

The rapid development of China’s healthcare industry has made scientist-led entrepreneurship a prevailing trend. The continuous return of high-caliber overseas talent has further accelerated the wave of innovation and startups in the medical sector. However, amid uncertainties in the international landscape—particularly those stemming from Sino-U.S. tensions—many areas of international cooperation, including basic research, clinical trials, and healthcare investment, have been significantly impacted. How should China’s healthcare sector maintain its global connectivity? What challenges and opportunities does the current global environment present for China’s healthcare industry?

This week, the Baidu App and VCBeat invited Lai Zhigang, Partner at Kaixuan Venture Capital; Qian Tingzhi, Founding Partner at Jingxu Venture Capital; Yang Ruirong, Partner at Yuanyi Capital; Zhu Yibo, Partner at Tonghe Yucheng Capital; and Dr. Lei Youning, Chief Technology Officer at Tiankeya, a representative medical enterprise. Together, they focused on the healthcare sector, engaging in in-depth discussions on hot topics in domestic and international healthcare in the post-pandemic era, and exploring the development prospects and innovative measures for the medical industry in the new era.

Live Broadcast Time: December 11 (Friday) 10:30 [Beijing Time]

December 10 (Thursday) 18:30 [Pacific Time]

December 10 (Thursday) 21:30 [Eastern Time]

Live Stream Link: Scan the QR code on the poster to enter the live room